Trials / Completed
CompletedNCT00311844
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desloratadine |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2005-05-28
- Completion
- 2005-05-28
- First posted
- 2006-04-06
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00311844. Inclusion in this directory is not an endorsement.